Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.43 |
| ▸ | FNTA | P49354 | 6/20 | 0.40 |
| ▸ | FNTB | P49356 | 6/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | GRN | P28799 | 1/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20132290 | 1.00 | AKT1 (0.43) | AKT1FNTAFNTBACEP2RY12 | |
| SCHEMBL31235812 | 0.93 | AKT1 (0.42) | AKT1ACEP2RY12NOD1 | |
| SCHEMBL15919172 | 0.91 | AKT1 (0.41) | AKT1FNTAFNTBACEP2RY12 | |
| SCHEMBL16273727 | 0.91 | AKT1 (0.41) | AKT1FNTAFNTBACEP2RY12 | |
| SCHEMBL24175784 | 0.88 | AKT1 (0.40) | AKT1FNTAFNTBP2RY12 | |
| SCHEMBL16273770 | 0.83 | AKT1 (0.36) | AKT1ACEP2RY12 | |
| SCHEMBL23953418 | 0.83 | AKT1 (0.39) | AKT1ACEP2RY12 | |
| SCHEMBL23953536 | 0.82 | ACE (0.36) | AKT1FNTAFNTBACEP2RY12 | |
| SCHEMBL15919123 | 0.82 | FOLH1 (0.49) | FNTAFNTB | |
| SCHEMBL16273731 | 0.82 | FOLH1 (0.49) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220354959-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC. (US) | 2022-11-10 | — | — | US | disclosed |
| EP-3901162-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | AbbVie Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3901162-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | AbbVie Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-109476699-B | Glucocorticoid receptor agonists and immunoconjugates thereof | 艾伯维公司 | 2021-10-12 | — | — | CN | disclosed |
| EP-3464318-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | AbbVie Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354959-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | AKT1 3898/4885FNTA 1179/4885FNTB 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.